- Conditions
- Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
- Interventions
- Methylphenidate extended-release liquid formulation
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced May 21, 2026, 8:05 PM EDT